12th Jul 2005 13:00
SECOND QUARTER 2005 RESULTS DATE NOTIFICATION - 28 July 2005Basingstoke, UK and Philadelphia, US - 12 July 2005 - Shire PharmaceuticalsGroup plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) will announce second quarter 2005US GAAP earnings on Thursday, July 28, 2005.Results announcement time: 12:00 BST / 07:00 EDT Conference call time: 14:00 BST / 09:00 EDT Live conference call:Matthew Emmens, Chief Executive Officer and Angus Russell, Chief FinancialOfficer will host the live conference call at 14:00 BST/09:00 EDT.Please RSVP [email protected] (T: +44 (0)1256 894 160).The details of the live conference call are as follows:UK dial in 01452 568 061 US / Canada dial in 1866 224 2972 Password Shire Live Webcast:The call will also be available live over the Internet via audio webcast,accessible through www.shire.com in the investor relations section. A slidepresentation to accompany the call will also be available on the Shire website.Replay:A replay of the presentation will be available for two week. Details are asfollows:UK dial in 0845 245 5205 US dial in 18662474222 Stnd Int Dial In Number +44 (0) 1452 55 00 00 Pin code 7659744 # Webcast Replay www.shire.com, in the investor relations section If you have any problems accessing this, please contact: Souheil Salah on: +44(0) 1256 894160First Half 2005 IFRS InformationUK Listing Authority (UKLA) rules require listed companies to prepare groupaccounts in accordance with International Financial Reporting Standards("IFRS") for accounting periods beginning on or after 1 January 2005. Shirepreviously prepared group accounts in accordance with UK GAAP under the UKLArules. To comply with this new obligation, Shire will publish its interimresults for the six months ended 30 June 2005 in accordance with IFRS inSeptember 2005, together with its IFRS accounting policies, IFRS restatementsof previously published results, and reconciliations to previously publishedresults, as required by IFRS1, First-time adoption of International FinancialReporting Standards.For further information please contact:Investor Relations Souheil Salah (Rest of the World) +44 1256 894 160 Heidi Wunder (North America) +1 484 595 8709 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com. 2Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire